Skip to content
Plasma-Safe-SeqS
RAS-RAF-SEQ

Detection of mutations impacted by RAS-RAF and PI3K pathways

RAS-RAF-SEQ detects mutations in the five most relevant targets for cancers (e.g., colorectal, pancreatic, gallbladder, ovarian, and lung) impacted by the RAS-RAF and PI3K signaling pathways. RAS-RAF-SEQ can track key mutations with maximum efficiency for therapy selection (EGFR treatment or other targeted treatments), monitoring therapeutic efficacy of treatments, identifying treatment resistance, detecting MRD, and avoiding over-treatment -maximizing quality of life during treatment.

Panel features

CLIA-validated, ultra-sensitive blood test for the detection of BRAF, KRAS, NRAS, AKT1, and PIK3CA. This panel detects as few as 7 mutant molecules in a background of 20,000 wild-type molecules (0.035% mutant allele frequency).

GENE EXON EXAMPLES FOR COVERED ALTERATIONS WITH KNOWN CLINICAL RELEVANCE
AKT1 2 E17K [c49G>A]
BRAF 6, 11, 15 V600X [c1799T>A/C/G, c.1798_1799delinAA, c1798G>A/C/T and others]
KRAS 2, 3, 4 G12X [c.35G>A/C/T, c.34G>A/C/T, c.34_35delinsTT and others]
G13X [c.38G>A/C/T, c.37G>A/C/T, c.38_39delinsAT and others]
G61X [c.183A>C/G/T, c.182A>C/G/T, c.181C>A/G and others]
NRAS 2, 3, 4 G12X [c.35G>A/C/T, c.34G>A/C/T, c.34_35delinsAA and others]
G13X [c.38G>A/C/T, c.37G>A/C/T, c.37_38delinsAA and others]
Q61X [c.183A>C/G/T, c.182A>C/G/T, c.181C>A/G and others]
PIK3CA 1, 2, 4, 5, 7, 8, 9, 13, 18, 20 C420R [c.1258T>C]
E545X [c.1635G>A/C/T, c.1634A>C/G/T, c.1633G>A/C]
M10431 [c.3129G>T], H1047X [c.3140A>G/T, c.3139G>T]
Contact

We’d love to hear from you!

Hidden
Hidden
Hidden
Hidden
Hidden
Hidden